페이지 정보작성자 : NMSNUH 작성일2017-02-20 조회2,122회 댓글0건
Koh Chang-Soon International Fellowship Program for Nuclear Medicine
Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA invites applications for
Fellowship Program for Nuclear Medicine Physician in Asia.
Scholars from all over the world have come to be trained for a period of one week to six months under ‘IAEA Collaborating
Center for Nuclear Medicine’ at Seoul National University, which was established by IAEA in 2004. A new opportunity of
international fellowships started in 2010, which supported the following three visiting scholars. Whether a physician, scientist, or engineer, future international visiting fellows will now be part of the ‘Koh Chang-Soon Fellowship Program’.
#1. Jefferson Rivera Pagsisihan: St. Luke's Medical Center: Tagaytay Hospital and Medical Center, Phillippines 2010. 6. 10 – 2011. 5. 30
#2. Amitabh Arya: Sanjay Gandhi Post Graduate Institute of Medical Sciences, India. 2011. 5. 16 – 2012. 5. 15
#3. Budiwan Hendra: Mochtar Riady Comprehensive Cancer Center, Indonesia. 2012. 5. 21 – 2013. 5. 30
#4. Muhammad Kashif Rahim: Multal Institute of Nuclear Medicine and Radiotherapy, Nishtal Medical College and Hospital, Multan, Pakistan. 2013.4.29 – 2014.4.28
#5. Jamilla Cecilia Llanes Gomez: St. Luke's Medical Center, Quezon City and Global City, Philippine. 2014. 3 – 2015. 3
#6. Su Thet Oo: North Okkalapa General Hospital, Ministry of Health, Myanmar. 2014.3 – 2015. 3
#7. Azmal Kabir Sarker. Insitute of Nuclear Medicine & Ultrasound, BAEC, BSMMI campus, Shahbag, Dhaka, Bangladesh. 2014. 3 – 2015. 3
#8. Bolormaa Ganbaatar: Imaging Diagnostics Center, State Center Hospital Mongolla. 2015.03 -
#9. Apichaya Claimon: Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. 2015.03 -
#10. Mohammad Anwar-UL Azim: National Institute of Nuclear Medicine & Allied Sciences (NINMAS), Bangladesh Atomic Energy Commission (BAEC), Bangladesh. 2015.05 -
The Department of Nuclear Medicine (http://nm.snu.ac.kr/emain) performs cutting-edge research and comprehensive education through collaborating and networking with outstanding researchers and international parties. Fifteen faculties and over 40 researchers with backgrounds in medicine, physics, chemistry, pharmacology, and biology get involved in multidisciplinary researches. The clinical research improves patient care by developing, applying and conducting clinical trials for new materials and methods using PET/CT, radiopharmaceuticals, imaging analysis, brain receptor imaging, and radionuclide targeted therapy. The research topics in basic nuclear medicine include the development of new radiopharmaceuticals, new technologies for the analysis of nuclear imaging, and new equipment such as PET/MRI and small animal PET. Another important advanced research field is in vivo molecular imaging which detects the expression of specific genes, biomarker, and cell trafficking using optical imaging, nano-particles as well as radioisotopes. Our department was designated as IAEA Collaborating Center for Nuclear Medicine and Molecular Imaging for research and training at December 2004. We are proud that all the faculty members act as international leaders in advanced research, education and training.
Recent research topics
l Translational research using multifunctional nano-particles for optical/PET/MRI imaging and drug or gene delivery
l Translational research of targeted imaging & therapy using reporter genes, peptides, aptamers and microRNAs
l In vivo cell trafficking of stem cells or immune cells using bioluminescence, fluorescence, radio-labeling, and MRI technology
l In vivo molecular imaging of neurochemistry and neuropsychology
l Developing PET/MRI, animal PET & SPECT, and image analysis softwares
l Developing novel radiopharmaceuticals targeting heart, brain, inflammation and diverse cancers
l Test of biodistribution, pharmacokinetics, and efficacy of new drug (including small molecules and bio-drugs) using in vivo imaging
l Clinical trials using angiogenesis PET and amyloid-beta PET for Alzheimer’s disease
Keon Wook KANG, M.D., Ph.D., Professor
- As a nuclear medicine physician and molecular imaging scientist, he teaches nuclear medicine oncology in both clinical and research aspects. He and his colleagues perform translational research on molecular imaging and molecular targeted therapy using multifunctional nano-particles through in vivo imaging and clinical trials, especially on cancer. His group participates in vivo validation of new drugs and drug delivery system using multimodal in vivo imaging as well as clinical studies using PET and SPECT. He also facilitates international collaboration involving the academic, research, and industrial sectors.
June-Key CHUNG, M.D., Ph.D., Professor
- An internationally recognized expert in the field of nuclear medicine, Dr. Chung has pioneered numerous techniques for developing new and powerful in vivo molecular imaging tools and anti-cancer therapies. His clinical and research work also has led to numerous peer-reviewed journal articles in nuclear medicine. Major research projects are related to visualize endogenous or exogenous tumor-related gene or protein expression including p53, HIF-1a, hTERT and microRNAs using nuclear or bioluminescence reporter genes such as sodium iodide symporter (NIS), thymidine kinase (TK), dopamine receptor (D2R) and luciferases. He has a particular interest on radionuclide gene therapy using NIS, which can uptake several therapeutic radionuclide such as 188Re, 131I. In addition, the development of new radio-immunotherapy to enhance the effects of cancer DNA vaccines by utilizing radioiodine gene therapy is another subject of his recent research.
Dong Soo LEE, M.D., Ph.D., Professor
- Dr. Lee has been doing clinical researches in nuclear neurology and brain mapping and clinical nuclear cardiology researches. His main achievement ranged from establishment of efficacy of gated SPECT in the evaluation of bypass graft surgery or new treatment modality such as intracoronary autologous bone marrow stem cell therapy, via application of mapping technology to the pre-operative evaluation of epilepsy patients using FDG PET or ictal SPECT, to the application of PET studies in the understanding of brain pathologies in profound deafness. His recent researches extended from the above clinical ones into the topics of pre-clicnial molecular imaging studies such as cell differentiation imaging in vivo using microPET/ microMRI and optical imaging methods. Adopting the very recent progresses of nanotechonolgy, he has just started to do in vivo nano-imaging studies. ‘MicroRNA imaging in vivo’ is just one example of these pursuits. He works with two research professors, SH Kim and HW Yoon, two post-docs and dozens of PhD candidate students and MD students.
Jae Min JEONG, M.D., Ph.D., Professor
- Our major research field is development of new radiopharmaceuticals labeled with positron emitters, gamma emitters and beta emitters. Radiopharmaceuticals are used for imaging functions of organs or tissues such as metabolism, receptor distribution, and blood flow. Recent developments of radiopharmaceuticals are closely related with molecular imaging and nanomedicine. In addition, we also develop therapeutic radiopharmaceuticals labeled with beta emitters such as Re-188, Y-90 and Lu-177.
Gi Jeong CHEON, M.D., PhD., Professor
-As a nuclear medicine physician and molecular imaging scientist, he has been performing clinical and basic reseach in nuclear oncology, radionuclide therapy, and nuclear cardiology. He and his colleagues perform clinical research on radionuclide therapy, radionuclide tumor imaging (PET, SPECT, and scintigraphy) and translational research on molecular imaging and molecular targeted therapy using tumor-specific radiotracers through in vivo imaging and clinical trials, especially on cancer. His recent researches extended from the above clinical and preclinical ones into the topics of PET/MR fusion molecular imaging studies on combinatory information of anatomical, physiological, and metabolic imaging modalities. He has published over 130 papers in peer-reviewed journals on nuclear medicine, molecular imaging, and radionuclide therapy. He has a continuing interest in radionuclide targeted therapy using multifunctional and target-specific radiotracers and tailored therapy using combined molecular imaging modalites.
Jae Sung LEE, Ph.D., Professor
- The research goal that we pursue is to develop the technologies with which we can acquire the biologically relevant and clinically useful information from human body and living animals. The current research interests of my laboratory included, but are not limited to, novel medical imaging systems, i.e. hybrid PET-MRI scanner, and advanced biomedical image analysis technologies. We are especially focusing on the radiotracer imaging modalities, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT).